Adial Pharmaceuticals Inc Financials
This page shows Adial Pharmaceuticals Inc (ADIL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The development-stage model relies on external financing to fund recurring operating spending rather than reported revenue.
FY2025 operating cash flow was-$6.49M against an operating loss of-$7.80M , so cash needs closely track the reported cost structure rather than reflecting a purely non-cash accounting loss. Financing supplied$8.47M that year, covering the operating outflow while the company reports no revenue; the model therefore depends on capital access before customer receipts are reported.
The spending mix helps explain persistent losses: FY2025 selling, general and administrative expense was
At FY2025 year-end, liabilities were modest at
Financial Health Signals
Adial Pharmaceuticals Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Adial Pharmaceuticals Inc earned -$11.93 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Adial Pharmaceuticals Inc held $5.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
Adial Pharmaceuticals Inc invested $2.6M in research and development in fiscal year 2025. This represents a decrease of 18.9% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
ADIL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $440K+1.7% | $433K | N/A | $521K-28.8% | $732K-2.0% | $747K | N/A | $1.0M |
| SG&A Expenses | $5.4M+244.2% | $1.6M | N/A | $1.2M+8.1% | $1.1M-24.4% | $1.5M | N/A | $1.2M |
| Operating Income | -$52.0M-2499.3% | -$2.0M | N/A | -$1.8M+6.3% | -$1.9M+17.0% | -$2.3M | N/A | -$2.2M |
| Net Income | -$52.0M-2469.9% | -$2.0M | N/A | -$1.8M+8.4% | -$2.0M+12.2% | -$2.2M | N/A | -$2.2M |
| EPS (Diluted) | -$11.25 | -$1.48+87.1% | -$11.48 | -$0.08 | -$4.61 | -$8.52-5580.0% | -$0.15+60.5% | -$0.38 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
ADIL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $29.1M+456.5% | $5.2M-21.7% | $6.7M+17.9% | $5.7M-16.8% | $6.8M+97.1% | $3.5M-31.6% | $5.0M-24.9% | $6.7M |
| Current Assets | $28.8M+500.6% | $4.8M-22.3% | $6.2M+23.3% | $5.0M-17.5% | $6.1M+131.2% | $2.6M-35.2% | $4.1M-27.8% | $5.6M |
| Cash & Equivalents | $28.7M+526.3% | $4.6M-22.1% | $5.9M+27.7% | $4.6M-22.1% | $5.9M+150.0% | $2.4M-36.9% | $3.8M-27.9% | $5.2M |
| Total Liabilities | $67.5M+4367.7% | $1.5M+8.1% | $1.4M+21.0% | $1.2M-4.6% | $1.2M-8.6% | $1.3M+35.7% | $976K+17.7% | $829K |
| Current Liabilities | $5.1M+239.1% | $1.5M+8.1% | $1.4M+21.0% | $1.2M-4.6% | $1.2M-8.6% | $1.3M+35.7% | $976K+17.7% | $829K |
| Total Equity | -$38.4M-1132.5% | $3.7M-29.6% | $5.3M+17.1% | $4.5M-19.4% | $5.6M+162.9% | $2.1M-47.7% | $4.1M-30.9% | $5.9M |
| Retained Earnings | -$144.0M-56.5% | -$92.0M-2.2% | -$90.0M-2.3% | -$88.0M-2.1% | -$86.2M-2.3% | -$84.2M-2.7% | -$82.0M-2.6% | -$79.9M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ADIL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.4M-294.6% | -$1.6M-21.7% | -$1.3M+27.7% | -$1.8M-4.8% | -$1.7M-10.4% | -$1.6M-9.1% | -$1.5M+14.2% | -$1.7M |
| Investing Cash Flow | N/A | N/A | $0 | $0 | $0-100.0% | $150K | N/A | N/A |
| Financing Cash Flow | $25.2M+7895.6% | $315K-87.9% | $2.6M+395.3% | $525K-90.1% | $5.3M+10361.1% | $51K | $0-100.0% | $3.6M |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
ADIL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | -54.4% | N/A | -39.8%-4.8pp | -35.0%+69.8pp | -104.8% | N/A | -37.3% |
| Return on Assets | -178.7%-140.0pp | -38.7% | N/A | -31.7%-2.9pp | -28.8%+35.8pp | -64.6% | N/A | -32.6% |
| Current Ratio | 5.63+2.5x | 3.18-1.2x | 4.42+0.1x | 4.34-0.7x | 5.02+3.0x | 1.99-2.2x | 4.16-2.6x | 6.78 |
| Debt-to-Equity | N/A | 0.41+0.1x | 0.260.0x | 0.260.0x | 0.22-0.4x | 0.62+0.4x | 0.24+0.1x | 0.14 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Adial Pharmaceuticals Inc Ranks
Frequently Asked Questions
What is Adial Pharmaceuticals Inc's operating cash flow?
Adial Pharmaceuticals Inc (ADIL) recorded an outflow of $6.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Adial Pharmaceuticals Inc's total assets?
Adial Pharmaceuticals Inc (ADIL) had $6.7M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Adial Pharmaceuticals Inc spend on research and development?
Adial Pharmaceuticals Inc (ADIL) invested $2.6M in research and development during fiscal year 2025.
What is Adial Pharmaceuticals Inc's current ratio?
Adial Pharmaceuticals Inc (ADIL) had a current ratio of 4.42 as of fiscal year 2025, which is generally considered healthy.
What is Adial Pharmaceuticals Inc's debt-to-equity ratio?
Adial Pharmaceuticals Inc (ADIL) had a debt-to-equity ratio of 0.26 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
How does Adial Pharmaceuticals Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Adial Pharmaceuticals Inc (ADIL) held $5.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $6.5M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.